Dossier assessment
Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
| Adults with asthma not adequately controlled with a maintenance combination of a LABA and a high dose of an ICS who experienced one or more asthma exacerbations in the previous year |
Result of dossier assessment:
| No statistically significant differences in any outcome; added benefit not proven |
Additional information
Federal Joint Committee (G-BA)
2021-02-04: A G-BA decision was published.
Project details
- Project no.
- A20-69
- Commission
- Commission awarded on 07.08.2020 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
Connected Projects
-
Addendum
Indacaterol acetate/glycopyrronium bromide/mometasone furoate (asthma) - Addendum to Commission A20-69
Status: Commission completed